MedPath

Influvac

Brand Name: Influvac

Generic Name: Trivalent Influenza Vaccine (Surface Antigen) 2025 Southern Hemisphere Strain

Active
Registration Number

BR-901

Dosage Form

Suspension for Injection (IM/SC)

Issuance Date

March 24, 2025

Expiry Date

March 24, 2026

Product Information

Philippine FDA product specifications and classification details

Product Specifications

Dosage StrengthEach dose (0.5 mL) contains the following strains*: (A/Victoria/4897/2022, IVR-238) A/Victoria/4897/2022 (H1N1) pdm09-like virus A/Croatia/10136RV/2023 (H3N2) - like virus (A/Croatia/10136RV/2023, X-425A) 15 ug HA** 15 ug HA** 15 ug HA** B/Austria/1359417/2021 - like strain virus (B/Austria/1359417/2021 - BVR-26) *Propagated in embryonated chicken eggs **Haemagglutinin
Packaging0.5 mL in 1 mL USP Type I pre-filled glass syringe with grey bromobutyl rubber plunger with needle (Box of 1's and 10's)

Classification

C
Classification
Prescription Drug (RX)
P
Pharmacologic
Vaccines
A
Application
Monitored Release (Strain Clearance)
Philippine FDA Classification

Active Ingredients (1)

Complete list of active ingredients in this pharmaceutical product.

Trivalent Influenza Vaccine (Surface Antigen) 2025 Southern Hemisphere StrainActive
Monograph: trivalent influenza vaccine (surface antigen) 2025 southern hemisphere strain

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

Product

Company

Legal

© 2025 MedPath, Inc. All rights reserved.

MedPath - Medical Intelligence Platform